Picture [iito] Life Science Business Portals Media Data 2022 650x100px
Organisation › Details

ADC Therapeutics S.A. (NYSE: ADCT)

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. *


Period Start 2012-03-26 established pred
  Group ADC Therapeutics (Group)
  Predecessor ADC Therapeutics S.à.r.l. (ADCT)
Products Industry antibody-drug conjugates (ADC) technology
  Industry 2 cancer drug
Persons Person Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co)
  Person 2 Gilman, David (ADC Therapeutics 202206– Chief Business + Strategy Officer before ClearView Healthcare Partners)
Region Region Epalinges VD
  Country Switzerland
  Street 3B Route de la Corniche
  City 1066 Epalinges VD
  Tel +41-21-653-0200
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2021-12-31)
  Currency USD
  Annual sales 33,917,000 (revenue, total, consolidated (2021) 2021-12-31)
  Profit -230,026,000 (2021-12-31)
  Cash 466,544,000 (2021-12-31)
    * Document for �About Section�: ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne.
Record changed: 2022-06-13


Picture [iito] Made Without Love 650x100px

More documents for ADC Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top